Enlicitide vs RBD7022

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline

Enlicitide · Lipfendra

Marketed by Merck & Co.

Phase 3 in Atherosclerotic Cardiovascular Diseasepeptide
Reliable signal

NCT05952856 · Phase 3 · completed

This was a randomized, triple-blind, placebo-controlled Phase 3 trial in 2,909 adults with hypercholesterolemia. The primary endpoint was the mean percent change in LDL-C from baseline to Week 24, a standard regulator-accepted efficacy measure for lipid-lowering therapy. The active arm achieved a significantly greater LDL-C reduction than placebo (-57.1% vs +3.0%, p<0.001), so the trial met its primary endpoint with a large effect size and low risk of bias.

Next expected readout: November 2027 · NCT07821944 (registry estimate)

Reported efficacy

Mean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 24 (Baseline and Week 24); Number of Participants With One or More Adverse Events (AEs) (Up to 60 weeks); Number of Participants Who Discontinued Study Drug Due to an AE (Up to 52 weeks): Week 24 LDL-C mean percent change: -57.1% with enlicitide vs 3.0% with placebo; difference -55.8 percentage points (95% CI -60.9 to -50.7; p<0.001). (met)

Result source: NCT05952856

RBD7022

Developed by Suzhou Ribo Life Science

Phase 1 in Atherosclerotic Cardiovascular DiseaseRNAi (siRNA)
Weak signal

NCT05912296 · Phase 1 · completed

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants with Treatment Related Adverse Events as Assessed by CTCAE v5.0". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Reported efficacy

Number of Participants with Treatment Related Adverse Events as Assessed by CTCAE v5.0 (SAD up to Day 180; MAD up to Day 208): Using PCSK9 levels as a marker of target engagement, in patients with and without statin background therapy, RBD7022 produced a maximal reduction of up to 75%, with that level of suppression maintained at 6 months of follow-up.

Result source: NCT05912296

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEnlicitideRBD7022
LDL-C, % change-58.2% vs 2.6%−60.8 vs placebowk 24 · n 198NCT05952869
6 other results
  • -64.6% vs -36.5% wk 8 · n 101 · Phase 3 · primary NCT06450366
  • -55.3% vs 8.7% wk 52 · n 193 · Phase 3 · secondary NCT05952869
  • -59.7% vs 1.2% 30 mg · wk 8 · n 73 · Phase 2 · primary NCT05261126
  • -57.9% vs 1.2% 18 mg · wk 8 · n 74 · Phase 2 · primary NCT05261126
  • -54.5% vs 1.2% 12 mg · wk 8 · n 75 · Phase 2 · primary NCT05261126
  • -40% vs 1.2% 6 mg · wk 8 · n 75 · Phase 2 · primary NCT05261126
—Not reported
Non-HDL-C, % change-52.3% vs 2.1%−54.4 vs placebowk 24 · n 198NCT05952869
5 other results
  • -58% vs -31.8% wk 8 · n 101 · Phase 3 · secondary NCT06450366
  • -54.3% vs 1.5% 30 mg · wk 8 · n 73 · Phase 2 · secondary NCT05261126
  • -51.8% vs 1.5% 18 mg · wk 8 · n 74 · Phase 2 · secondary NCT05261126
  • -49% vs 1.5% 12 mg · wk 8 · n 76 · Phase 2 · secondary NCT05261126
  • -34.4% vs 1.5% 6 mg · wk 8 · n 74 · Phase 2 · secondary NCT05261126
—Not reported
ApoB, % change-48.2% vs 1.8%−50 vs placebowk 24 · n 197NCT05952869
5 other results
  • -54.6% vs -27.7% wk 8 · n 101 · Phase 3 · secondary NCT06450366
  • -51.8% vs 0% 30 mg · wk 8 · n 74 · Phase 2 · secondary NCT05261126
  • -48.7% vs 0% 18 mg · wk 8 · n 74 · Phase 2 · secondary NCT05261126
  • -45.8% vs 0% 12 mg · wk 8 · n 75 · Phase 2 · secondary NCT05261126
  • -32.8% vs 0% 6 mg · wk 8 · n 76 · Phase 2 · secondary NCT05261126
—Not reported
Lp(a), % change-24.7% vs -1.6%−23.1 vs placebowk 24 · n 196NCT05952869
1 other result
  • -26.2% vs 10.4% wk 8 · n 101 · Phase 3 · secondary NCT06450366
—Not reported
3-point MACE (% with event)—Not posted · NCT07216482—Not reported

LDL-C, % change

Enlicitide
-58.2% vs 2.6%−60.8 vs placebowk 24 · n 198NCT05952869
6 other results
  • -64.6% vs -36.5% wk 8 · n 101 · Phase 3 · primary NCT06450366
  • -55.3% vs 8.7% wk 52 · n 193 · Phase 3 · secondary NCT05952869
  • -59.7% vs 1.2% 30 mg · wk 8 · n 73 · Phase 2 · primary NCT05261126
  • -57.9% vs 1.2% 18 mg · wk 8 · n 74 · Phase 2 · primary NCT05261126
  • -54.5% vs 1.2% 12 mg · wk 8 · n 75 · Phase 2 · primary NCT05261126
  • -40% vs 1.2% 6 mg · wk 8 · n 75 · Phase 2 · primary NCT05261126
RBD7022
—Not reported

Non-HDL-C, % change

Enlicitide
-52.3% vs 2.1%−54.4 vs placebowk 24 · n 198NCT05952869
5 other results
  • -58% vs -31.8% wk 8 · n 101 · Phase 3 · secondary NCT06450366
  • -54.3% vs 1.5% 30 mg · wk 8 · n 73 · Phase 2 · secondary NCT05261126
  • -51.8% vs 1.5% 18 mg · wk 8 · n 74 · Phase 2 · secondary NCT05261126
  • -49% vs 1.5% 12 mg · wk 8 · n 76 · Phase 2 · secondary NCT05261126
  • -34.4% vs 1.5% 6 mg · wk 8 · n 74 · Phase 2 · secondary NCT05261126
RBD7022
—Not reported

ApoB, % change

Enlicitide
-48.2% vs 1.8%−50 vs placebowk 24 · n 197NCT05952869
5 other results
  • -54.6% vs -27.7% wk 8 · n 101 · Phase 3 · secondary NCT06450366
  • -51.8% vs 0% 30 mg · wk 8 · n 74 · Phase 2 · secondary NCT05261126
  • -48.7% vs 0% 18 mg · wk 8 · n 74 · Phase 2 · secondary NCT05261126
  • -45.8% vs 0% 12 mg · wk 8 · n 75 · Phase 2 · secondary NCT05261126
  • -32.8% vs 0% 6 mg · wk 8 · n 76 · Phase 2 · secondary NCT05261126
RBD7022
—Not reported

Lp(a), % change

Enlicitide
-24.7% vs -1.6%−23.1 vs placebowk 24 · n 196NCT05952869
1 other result
  • -26.2% vs 10.4% wk 8 · n 101 · Phase 3 · secondary NCT06450366
RBD7022
—Not reported

3-point MACE (% with event)

Enlicitide
—Not posted · NCT07216482
RBD7022
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

RBD7022: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Enlicitide: 3 of 4 rows · RBD7022: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEnlicitide
Dropout rate
—20 mga
NCT05952856 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 11 more results
3%
NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
—20 mg
NCT06450366 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
1%Enlicitide
NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
2.6%30 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
2.6%18 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
0%12 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
2.6%6 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
0%Panel A: Moderate Renal Impairment
NCT05934292 · Phase 1 · registry result, not featured evidence
0%Panel B: Severe RI
NCT05934292 · Phase 1 · registry result, not featured evidence
11.1%Panel C: End-Stage Renal Disease (
NCT05934292 · Phase 1 · registry result, not featured evidence
0%Panel D: Healthy Controls
NCT05934292 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—20 mga
NCT05952856 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 11 more results
—
NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
—20 mg
NCT06450366 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
—Enlicitide
NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
—30 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
—18 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
—12 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
—6 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
—Panel A: Moderate Renal Impairment
NCT05934292 · Phase 1 · registry result, not featured evidence
—Panel B: Severe RI
NCT05934292 · Phase 1 · registry result, not featured evidence
—Panel C: End-Stage Renal Disease (
NCT05934292 · Phase 1 · registry result, not featured evidence
—Panel D: Healthy Controls
NCT05934292 · Phase 1 · registry result, not featured evidence
Serious AEs
9.9%20 mga
NCT05952856 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 11 more results
4.5%
NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
0%20 mg
NCT06450366 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
—Enlicitide
NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
2.6%30 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
2.6%18 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
3.9%12 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
1.3%6 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
0%Panel A: Moderate Renal Impairment
NCT05934292 · Phase 1 · registry result, not featured evidence
0%Panel B: Severe RI
NCT05934292 · Phase 1 · registry result, not featured evidence
11.1%Panel C: End-Stage Renal Disease (
NCT05934292 · Phase 1 · registry result, not featured evidence
0%Panel D: Healthy Controls
NCT05934292 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
a
nasopharyngitis 9.4% (placebo 7.9%)
influenza 8.4% (placebo 8.9%)
accidental overdose 7.9% (placebo 4%)
NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 9 more results
20 mg
accidental overdose 0%
NCT06450366 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3
30 mg
covid-19 5.3% (placebo 9.3%)
arthralgia 2.6% (placebo 1.3%)
nausea 2.6% (placebo 0%)
NCT05261126 · Phase 2 · registry result, not featured evidence
18 mg
covid-19 6.6% (placebo 9.3%)
nausea 5.3% (placebo 0%)
diarrhoea 3.9% (placebo 1.3%)
NCT05261126 · Phase 2 · registry result, not featured evidence
12 mg
dyspepsia 6.6% (placebo 1.3%)
arthralgia 5.3% (placebo 1.3%)
fatigue 3.9% (placebo 6.7%)
NCT05261126 · Phase 2 · registry result, not featured evidence
6 mg
covid-19 7.8% (placebo 9.3%)
diarrhoea 6.5% (placebo 1.3%)
dyspepsia 1.3% (placebo 1.3%)
NCT05261126 · Phase 2 · registry result, not featured evidence
dry mouth 12.5%
hypertension 12.5%
animal bite 0%
NCT05934292 · Phase 1 · registry result, not featured evidence
animal bite 12.5%
orthostatic hypotension 12.5%
dry mouth 0%
NCT05934292 · Phase 1 · registry result, not featured evidence
animal bite 0%
dry mouth 0%
hypertension 0%
NCT05934292 · Phase 1 · registry result, not featured evidence
animal bite 0%
dry mouth 0%
hypertension 0%
NCT05934292 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 8 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Enlicitide

LDL-C -59.7% (n=73) vs 1.2% (n=72) placebo @ 8wk30 mg
percent change · % of baseline
NCT05261126 · Phase 2 · registry result, not featured evidence
show 6 more results
-57.9% (n=74) vs 1.2% (n=72) placebo @ 8wk18 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
-54.5% (n=75) vs 1.2% (n=72) placebo @ 8wk12 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
-40% (n=75) vs 1.2% (n=72) placebo @ 8wk6 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
-58.2% (n=198) vs 2.6% (n=96) placebo @ 24wk
NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-55.3% (n=193) vs 8.7% (n=94) placebo @ 52wk
NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-64.6% (n=101) vs -6.3% (n=50) Bempedoic Acid @ 8wk
NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
Non-HDL-C -54.3% (n=73) vs 1.5% (n=72) placebo @ 8wk30 mg
percent change · % of baseline
NCT05261126 · Phase 2 · registry result, not featured evidence
show 5 more results
-51.8% (n=74) vs 1.5% (n=72) placebo @ 8wk18 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
-49% (n=76) vs 1.5% (n=72) placebo @ 8wk12 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
-34.4% (n=74) vs 1.5% (n=72) placebo @ 8wk6 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
-52.3% (n=198) vs 2.1% (n=96) placebo @ 24wk
NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-58% (n=101) vs -5.2% (n=50) Bempedoic Acid @ 8wk
NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
Apo B -51.8% (n=74) vs 0% (n=72) placebo @ 8wk30 mg
percent change · % of baseline
NCT05261126 · Phase 2 · registry result, not featured evidence
show 5 more results
-48.7% (n=74) vs 0% (n=72) placebo @ 8wk18 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
-45.8% (n=75) vs 0% (n=72) placebo @ 8wk12 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
-32.8% (n=76) vs 0% (n=72) placebo @ 8wk6 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
-48.2% (n=197) vs 1.8% (n=97) placebo @ 24wk
NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-54.6% (n=101) vs -5.4% (n=50) Bempedoic Acid @ 8wk
NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
Lp(a -24.7% (n=196) vs -1.6% (n=96) placebo @ 24wk
percent change · % of baseline
NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 1 more result
-26.2% (n=101) vs 8.1% (n=50) Bempedoic Acid @ 8wk
NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
LDL-C Less Than 70 and 50% Reduction 70.8% (n=202) vs 1% (n=101) placebo @ 24wk
responder rate · % of participants
NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 1 more result
81.2% (n=101) vs 2% (n=50) Bempedoic Acid @ 8wk
NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
LDL-C Less Than 5.5 and 50 Pct Reduction 67.3% (n=202) vs 1% (n=101) placebo @ 24wk
responder rate · % of participants
NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 1 more result
78.2% (n=101) vs 2% (n=50) Bempedoic Acid @ 8wk
NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
LDL-C Goal Attainment 90.8% (n=76) vs 9.3% (n=75) placebo @ 8wk30 mg
responder rate · % of participants
NCT05261126 · Phase 2 · registry result, not featured evidence
show 3 more results
90.8% (n=76) vs 9.3% (n=75) placebo @ 8wk18 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
85.5% (n=76) vs 9.3% (n=75) placebo @ 8wk12 mg
NCT05261126 · Phase 2 · registry result, not featured evidence
80.5% (n=77) vs 9.3% (n=75) placebo @ 8wk6 mg
NCT05261126 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Enlicitide's landscape · RBD7022's landscape